Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$53.56 - $87.99
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.74M
Market Cap
$16.24B
Enterprise Value$11.16B
Total Cash (Recent Filing)$2.42B
Total Debt (Recent Filing)$42.41M
Price to Earnings (P/E)18.9
Beta0.53
Next Earnings
Nov 04, 2025EPS Estimate
1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding195,276,140
10 Day Avg. Volume1,802,270
30 Day Avg. Volume1,740,239
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit2.62
Enterprise Value/Ebitda8.23
Forecast
1Y Price Target
$85.00Price Target Upside1.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Long-term Growth PotentialThe new CEO highlighted confidence in INCY’s long-term growth potential driven by the existing commercial portfolio and maturing pipeline focusing on heme/onc and immunology.
Product Pipeline And Sales PotentialPovorcitinib has positive data in HS with potential for at least $1bn in sales across three indications, leveraging its differentiated mechanism of action.
Bears Say
Loss Of ExclusivityJakafi's late loss of exclusivity in 2028 poses a significant challenge, as it constitutes approximately 65% of total revenues.
Pipeline DelaysPipeline delays, including the JAK2V617Fi data delay, give pause to the company's longer-term outlook.
Incyte News
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $53.56 and its highest was $87.99 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $16.24B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Nov 04, 2025 which is in 47 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Jul 29, 2025. The company reported $1.572 earnings per share for the quarter, beating the consensus estimate of $1.401 by $0.171.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.6.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 195,276,140 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.572 in its last earnings report, beating expectations of $1.401. Following the earnings report the stock price went up 10.291%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in INCY
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$85.00 (1.31% Upside)
$85.00 (1.31% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 876.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.33%
12-Months-Change
Fundamentals
Return on Equity
24.30%
Trailing 12-Months
Asset Growth
24.87%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and successful product launches, particularly for Jakafi, Opzelura, and Niktimvo. However, increased R&D expenses and a delay in the regulatory timeline for V617F Phase I data were noted as challenges.View all INCY earnings summariesINCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$85.00
▲(1.31% Upside)
Technical Analysis
Ownership Overview
15.70% Insiders
22.90% Mutual Funds
0.60% Other Institutional Investors
34.48% Public Companies and
Individual Investors